Related Experiment Videos
Rapid cytokine release in cancer patients treated with interleukin-2
E Weidmann1, L Bergmann, J Stock
1Department of Internal Medicine, J.W. Goethe University, Frankfurt/M., Germany.
Insights
Recombinant interleukin-2 (IL-2) cancer therapy significantly increases tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) serum levels. Short infusions of IL-2 rapidly elevate TNF-alpha, IL-6, and interferon-gamma (IFN-gamma) more than continuous infusions.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Interleukin-2 (IL-2) is a cytokine used in cancer treatment.
- Understanding the cytokine response to IL-2 therapy is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the serum cytokine profiles in cancer patients receiving recombinant IL-2 (rIL-2).
- To compare the effects of short (1-h) versus continuous intravenous IL-2 infusions on cytokine levels.
Main Methods:
- Serum concentrations of IL-2, TNF-alpha, IFN-gamma, IL-6, IL-1, and IFN-alpha were measured using ELISA or RIA.
- Patients received rIL-2 via 1-h infusion or continuous 5-day intravenous infusion.
- Cytokine levels and their half-lives were analyzed over time.
Main Results:
- All patients showed increased TNF-alpha and IL-6 levels.
- 1-h IL-2 infusions induced rapid, high peaks of TNF-alpha, IL-6, and IFN-gamma compared to continuous infusions.
- IFN-gamma was consistently detected after 1-h infusions but only occasionally with continuous infusions.
- IL-1 and IFN-alpha were not detected.
- TNF-alpha levels had a longer half-life than administered recombinant TNF.
Conclusions:
- Short IL-2 infusions elicit a more pronounced and rapid cytokine response, particularly TNF-alpha, IL-6, and IFN-gamma.
- The kinetics suggest endogenous IL-2 synthesis following 1-h infusions.
- Cytokine profiles differ significantly based on IL-2 infusion strategy.
Abstract:
Serum concentrations of interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-6 (IL-6), interleukin-1 (IL-1) and interferon-alpha (IFN-alpha) were determined by commercially available enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA) in cancer patients treated with recombinant IL-2 (rIL-2) either as 1-h infusion (3 or 5 x 10(6)/m2) or continuous intravenous infusion for 5 days (3 x 10(6)/m2/day). A significant increase of TNF-alpha and IL-6 serum levels was observed in each patient. One-hour infusion of IL-2 induced a very rapid secretion of TNF-alpha, IL-6 and IFN-gamma with considerably higher peak levels than during IL-2 continuous intravenous infusion. IFN-gamma was released into the blood of all patients receiving IL-2 1-h infusion, but only occasionally during or after IL-2 continuous intravenous infusion. Neither IFN-alpha nor IL-1 were detectable in the serum before, during, or following IL-2 treatment in all patients studied. The kinetics of IL-2 after 1-h infusion fitted to a two-compartment model, suggesting the synthesis of considerable amounts of endogenous IL-2. Following IL-2 1-h infusion, rising TNF-alpha serum levels preceded the increase of serum IFN-gamma or IL-6. The serum peak levels of IFN-gamma and IL-6 decreased rapidly with a half-life of 0.29 to 2.5 h. The concentration time profiles of TNF following 1-h infusion of IL-2 demonstrated a considerably longer half-life than that of intravenously administered recombinant TNF as done in other studies.(ABSTRACT TRUNCATED AT 250 WORDS)